H. Shasha-Lavsky

Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.

J. Lieske, D. Magen, I. Bhan, 2022, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.

D. Magen, Y. Frishberg, T. Mcgregor, 2021, Genetics in medicine : official journal of the American College of Medical Genetics.

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.

J. Lieske, D. Magen, M. Sweetser, 2021, The New England journal of medicine.

Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1

J. Lieske, D. Magen, M. Sweetser, 2021, Kidney international reports.

Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial

D. Magen, M. Sweetser, Y. Frishberg, 2022, Pediatric Nephrology.

LB002ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)

J. Lieske, D. Magen, Y. Frishberg, 2020, Nephrology Dialysis Transplantation.

Long-term outcomes after pre-emptive liver transplantation in primary hyperoxaluria type 1

A. Dror, L. Kalfon, I. Weissman, 2022, Pediatric Nephrology.

Rituximab-associated hypogammaglobulinemia in children with idiopathic nephrotic syndrome: results of an ESPN survey

M. Marlais, Austin Waters, E. Volokhina, 2023, Pediatric Nephrology.

Chronic health conditions in Jewish Holocaust survivors born during World War II.

L. Keinan-Boker, S. Shasha, Hadas Shasha-Lavsky, 2015, The Israel Medical Association journal : IMAJ.

Treatment and long-term outcome in primary distal renal tubular acidosis.

F. Trepiccione, G. Gambaro, Z. Gucev, 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Genetic Markers Among the Israeli Druze Minority Population With End-Stage Kidney Disease.

O. Barel, A. Vivante, T. Paperna, 2023, American journal of kidney diseases : the official journal of the National Kidney Foundation.